Russell Barton
Operationeel Directeur bij ACUMEN PHARMACEUTICALS, INC.
Vermogen: 309 006 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Michela Gallagher | M | - |
AgeneBio, Inc.
 AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | 16 jaar |
| Daniel O'Connell | M | 54 | 18 jaar | |
| Steve Reynolds | M | - | 3 jaar | |
| Derek Meisner | M | 53 | 2 jaar | |
| Kimberlee Drapkin | F | 55 | 2 jaar | |
| Charles I. Clarvit | M | 68 |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | 11 jaar |
| Matthew Zuga | M | 58 | 3 jaar | |
| Nathan Fountain | M | 61 | 3 jaar | |
| Jeffrey Ives | M | 72 | 10 jaar | |
| Sean Stalfort | M | 53 | 6 jaar | |
| Laura Stoppel | M | 38 | 4 jaar | |
| Derrell Porter | M | 53 | 1 jaar | |
| Siew Tin Gan | F | - | - | |
| Ronald M. Nordmann | M | 82 |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | 11 jaar |
| Jasna Jerecic | M | - | - | |
| Amber Dilley | F | - | 3 jaar | |
| Julie Bockenstette | F | - | - | |
| Kathleen Pierce | F | - | - | |
| Kasey Spencer | M | - | - | |
| Rod Dowler | M | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Kenneth Payie | M | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Karen Ashe | F | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Janice Hitchcock | M | - | 6 jaar | |
| Alexandria Braun | F | - | 2 jaar | |
| Eric Siemers | M | 68 | 6 jaar | |
| Jim Doherty | M | 56 | - | |
| Darryle Schoepp | M | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Robyn Moxon | F | - | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Grant A. Krafft | M | - | 24 jaar | |
| William F. Goure | M | - | 15 jaar | |
| Jeffrey Sevigny | M | 55 | 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 31 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Russell Barton
- Persoonlijk netwerk
